“We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin. “We aim to cre...
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age a...
Depression affects nearly 300 million individuals worldwide and does not have a universally effective treatment. The US economic burden as a result of depr...
Insomnia is a sleep disorder with difficulty falling asleep or staying asleep, early awakening and so on. It is also the most common complaints in primary ...
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1 Approval is based on interim data from ongoin...
These models are essential for testing in vivo efficacy of novel therapeutics against lung cancer, elevating the prospects for significant advances in the ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) f...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Value-based care is a holistic, patient-centered healthcare model that focuses on a coordinated effort to help improve patient health outcomes and quality ...
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), announced that its IoNovo Iodine product has been gr...
Abrysvo is administered as a single dose injection into the muscle. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
© 2025 Biopharma Boardroom. All Rights Reserved.
